Alzheimer's Reading Room
|Senator Susan Collins|
The Spending Reductions through Innovations in Therapies or SPRINT, Act would invest in public-private partnerships to help ensure scientists and researchers are able to develop new, safe and effective drugs and other therapies to combat the most deadly and costly chronic diseases including Alzheimer's, cancer, diabetes, and heart disease.
These diseases are among the leading causes of death in the United States as well as the most costly to taxpayers.
|Subscribe to the Alzheimer's Reading Room|
"Alzheimer's and other chronic conditions take a tremendous personal and economic toll on millions of Americans and their families. Moreover, in addition to the human suffering they cause, they pose significant challenges to the fiscal health of our nation," said Senator Collins, who is Senate Co-chair of Congressional Task Force on Alzheimer's. "Our legislation is intended to speed the development of therapies to significantly modify, cure, or prevent these high-cost, chronic conditions. A relatively small federal investment today will offer millions of people hope, and it will also offer us an opportunity to control costs."
The SPRINT Act compresses the product development timelines and increases the volume of drugs in the development pipeline so that priority is given to the most promising pharmaceuticals. Additionally, it expedites the Food and Drug Administration (FDA) review process so that drugs can be brought more quickly to market to the patients who need them.
The legislation would save the federal government and taxpayers by working to cure the diseases that bear the greatest health care costs. It requires that every $1 in federal funds is matched by $2 in private investment so that federal dollars are best spent on market-tested and market-ready drugs. Alzheimer's disease alone will cost the nation $183 billion in 2012, 70 percent of which is covered by Medicare and Medicaid.
Senator Collins was joined by Senator Barbara Mikulski (D-Md.), a senior member of the Senate Health, Education, Labor and Pensions (HELP) Committee, as well as a cosponsor, Senator Richard Blumenthal (D-CT). They were joined by Representative Ed Markey (D-MA) who, along with Rep. Chris Smith (R-NJ), has introduced similar legislation in the House.
“I believe ‘honor thy mother and father’ is not just a good commandment to live by, it is good public policy to govern by,” Senator Mikulski said. “I’m so proud to introduce the SPRINT Act, which will help us sprint to the finish line by getting drugs through the valley of death from bench to bedside more quickly for chronic diseases like Alzheimer’s. By acting now, we can save billions in future health care spending and long term care costs. This bill saves lives and saves money. Through a public/private partnership that ensures each federal dollar is matched by two dollars in private investment, we can zero in on the diseases that are the most deadly and the most costly. Let’s put America’s biomedical innovation economy to work and bring an end to Alzheimer’s once and for all.”
"If we want to balance the federal budget, we must invest in medical research today,” said Congressman Edward J. Markey (D-Mass.), senior member of the House Energy and Commerce Committee. “We will only defeat high-cost chronic diseases like Alzheimer’s if we accelerate the discovery and development of safe and effective diagnostics and treatments. The SPRINT Act will support smart investments now that will save hundreds of billions of dollars in the years to come through promising potential therapies. Researchers currently do not have the funding to do a fraction of what they want to do and are ready to do. We need a government-wide commitment to defeating Alzheimer’s disease, and it must begin today.”
“Every day counts to the millions of people living with Alzheimer's and other chronic conditions and none of those days should be spent suffering without treatment,” said Sen. Kerry. “This legislation will help speed up the kinds of research and biotechnology that leads to life saving treatments that will save money. I’m proud to be part of a bipartisan team in Congress that’s working together to encourage these advancements in Massachusetts and across the country.”
“We are at a leadership moment in the Alzheimer's Movement,” said George Vradenburg, Co-Founder of USAgainstAlzheimer's and member of the national Advisory Council on Alzheimer's Research, Care, and Services. “Achieving the national goal of reducing healthcare costs by preventing or effectively treating Alzheimer's by 2025 or earlier requires us to jettison a 'business-as-usual' approach to drug discovery. The SPRINT Bill challenges us to rethink how we can increase the volume and velocity of effective treatments to patients suffering from multiple chronic conditions.”
In addition to USAgainstAlzheimer’s, it is supported by Alzheimer’s Association, American Health Assistance Foundation, Alzheimer’s Disease Research, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Foundation of America, Alliance for Aging Research, American Geriatric Society, Cure Alzheimer’s Fund, Janssen Alzheimer Immunotherapy, Colorado Access, Critical Path Institute, Geoffrey Beene Foundation Alzheimer’s Initiative, National Alliance for Caregiving, National Association of States United for Aging and Disabilities, National Family Caregiver’s Association, Retire Safe, and Volunteers of America.
Following introduction, the bill will move to the Senate HELP Committee for further debate.
More Insight and Advice for Caregivers
- How Alzheimer's Spreads Throughout the Brain
- Test Your Memory for Alzheimer's (5 Best Self Assessment Tests)
- What is Alzheimer's Disease?
- What is Dementia?
- What’s the Difference Between Alzheimer’s Disease and Dementia
- Communicating in Alzheimer's World
- How the Loss of Memory Works in Alzheimer’s Disease, and How Understanding This Could Help You
- Learning How to Communicate with Someone Suffering From Alzheimer's Disease
- Alzheimer's World -- Trying to Reconnect with Someone Suffering from Alzheimer's Disease
- Does the Combination of Aricept and Namenda Help Slow the Rate of Decline in Alzheimer's Patients
- Driving with Alzheimer's Can Mean Death
- About the Alzheimer's Reading Room
Original content Bob DeMarco, the Alzheimer's Reading Room